Form 4: Biogen Director Lloyd Minor Receives Equity Grant

Biogen Inc. director Lloyd Minor was granted 1,505 restricted stock units as part of his compensation package.

Summary

• Director Lloyd Minor acquired 1,505 restricted stock units (RSUs) of Biogen Inc. (BIIB) common stock.
• The transaction occurred on June 9, 2026.
• The shares were granted at a price of $0, representing standard equity compensation for board members.
• Following this transaction, Dr. Minor's total beneficial ownership of Biogen common stock increased to 3,875 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries no significant signal regarding company performance or outlook.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The restricted stock units are scheduled to vest on the earlier of the next annual meeting or the first anniversary of the grant date (June 9, 2027).

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector, intended to incentivize long-term oversight and alignment with shareholder value.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with compensation practices at large-cap pharmaceutical companies like Amgen, Gilead, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 1,505 restricted stock units on or before June 9, 2027.

Key Dates

Keywords

Biogen, BIIB, Form 4, Insider Trading, Equity Compensation, Director